Pregled bibliografske jedinice broj: 174883
Improving of biomonitoring strategy trough collaboration of clinical cytogenetics with genetical toxicology
Improving of biomonitoring strategy trough collaboration of clinical cytogenetics with genetical toxicology // Health Insurance in Transition:Biotechnology and Public Health: Expectations, Gains and Costs
Zagreb, 2002. (predavanje, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 174883 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Improving of biomonitoring strategy trough collaboration of clinical cytogenetics with genetical toxicology
Autori
Hitrec, Vlasta ; Fučić, Aleksandra ; Lasan, Ružica
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Health Insurance in Transition:Biotechnology and Public Health: Expectations, Gains and Costs
/ - Zagreb, 2002
Skup
5th International Conference Health Insurance in Transition ; Biotechnology and Public Health: Expectations, Gains and Costs
Mjesto i datum
Zagreb, Hrvatska, 26-28. 09
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Clinical cytogenetics; Genetical toxicology
Sažetak
For the last few decades genetical toxicology has been relying on unstable biomarkers such as chromosome aberrations, micronucleus frequency and sister chromated exchange frequency as indicator of genome damage after exsposure to mutagenic and carcinogenic agents. Although the basic aim of genetical toxicology is to evaluate the risk of cancer development, stable aberrations (translocations, inversions, deletions) critical in carcinogenesis have not been detected due to lack of sutible methods. The collaboration between clinical cytogenetics and genetical toxicology confirms mimportance of translocations.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
0108027
Ustanove:
Institut za medicinska istraživanja i medicinu rada, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Vlasta Hitrec
(autor)